Relapsed Hematologic Malignancy Clinical Trial
Official title:
ARIA: A Phase 1b/2, Open-label, Multi Cohort Trial of Tazemetostat in Combination With Various Treatments in Subjects With Relapsed or Refractory Hematologic Malignancies
This trial will study how safely the tazemetostat works with other therapies in various hematological malignancies. Hematologic malignancies are cancers that most often begin in the bone marrow or lymph nodes where blood precursors are produced. They are often called blood cancers and fall into three categories: leukemia, lymphoma and myeloma. Tazemetostat has been found to be a safe and effective drug that works in patients with follicular lymphoma where the disease has come back after treatment (known as relapsed) and when other treatment no longer works (known as refractory). Combining tazemetostat with other treatments may work better in treating patients with hematological malignancies and may improve disease response and durability of response.
This phase 1b/2 trial studies how safely the EZH2 inhibitor tazemetostat works with other therapies in various hematological malignancies. Tazemetostat has been found to be a safe and effective drug that works in patients with relapsed refractory (R/R) follicular lymphoma. Giving tazemetostat in combination with other treatments may work better in treating patients with hematological malignancies and may improve disease response and durability of response. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03096821 -
Extended Analysis for Leukemia/Lymphoma Treatment
|
||
| Recruiting |
NCT05956457 -
PRO and Wearable Data Insights From Individuals With R/R Multiple Myeloma
|
N/A | |
| Recruiting |
NCT03560882 -
A Pilot Trial of Atorvastatin in Tumor Protein 53 (p53) -Mutant and p53 Wild-Type Malignancies
|
Phase 1 | |
| Recruiting |
NCT03821519 -
Infusion of Donor Derived Cytokine Induced Killer (CIK) Cells in Hematological Patients Relapsed After Haploidentical Stem Cell Transplant
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05713214 -
Long-term Follow-up After Adoptive Transfer of Genetically Modified Cell Products
|
||
| Active, not recruiting |
NCT03413800 -
Len/Dex/DLI in Relapsed Multiple Myeloma After Allogeneic Stem Cell Transplant
|
Phase 2 | |
| Recruiting |
NCT05270096 -
International Leukemia Target Board
|
||
| Recruiting |
NCT03328078 -
A Study of CA-4948 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04327583 -
Impact of the Coordinated Intervention of the Healthcare Facilities Pharmacist and the Dispensary Pharmacist on the Care Pathway for Cancer Patients Treated With Oral Therapy
|
N/A |